Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
36
Participants
Timeline
Start Date
October 31, 2024
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Conditions
HIV
Interventions
DRUG
Letermovir
Letermovir 480mg PO once daily
All Listed Sponsors
collaborator
Royal Free Hospital NHS Foundation Trust
OTHER
lead
University College, London
OTHER
NCT06626555 - Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection | Biotech Hunter | Biotech Hunter